       Document 0124
 DOCN  M9460124
 TI    [Clinical study on ivermectin against 125 strongyloidiasis patients]
 DT    9404
 AU    Shikiya K; Zaha O; Niimura S; Uehara T; Ohshiro J; Kinjo F; Saito A;
       Asato R; First Department of Internal Medicine, Faculty of Medicine,;
       University of Ryukyus.
 SO    Kansenshogaku Zasshi. 1994 Jan;68(1):13-20. Unique Identifier : AIDSLINE
       MED/94186666
 AB    We treated 125 patients with strongyloidiasis (78 males and 47 females)
       by 2 oral doses of ivermectin (6 mg) at 2-week interval, and obtained
       the following results: 1. Eradication rate after treatment was 86.4%
       (108 of 125 patients), responsively. Out of the total 17 patients were
       resistant (non-responsive) to treatment, 8 patients received a further
       course of ivermectin and all Strongyloides stercoralis in their feces
       were eradicated. 2. Side effects were observed in 7.2% of the patients
       after the first dose treatment and in 3.2% after the second dose. But
       all symptoms were mild and self-limited. Although liver disfunction
       developed in 13.6% of the patients, no symptoms occurred and no special
       treatment was required. 3. Positive rate of anti-HTLV-I antibody in the
       resistant group was significantly higher (80.0%) than in the eradicated
       group (29.2%) and in the stool-negative group (0%). 4. Although
       eosinophils before treatment in the eradicated group was significantly
       higher than that of controls, there was no significant difference
       between the resistant group and controls. IgE levels in the resistant
       group was significantly lower than in the eradicated group. We would
       like to conclude that IVM is the best drug for treatment of the patient
       with Strongyloides stercoralis not only from this results but also our
       previous reports which had investigated the clinical efficacy on
       thiabendazole, mebendazole and albendazole.
 DE    Adult  Aged  Animal  Comparative Study  Drug Administration Schedule
       Drug Resistance  English Abstract  Female  Human  HTLV-I
       Antibodies/ANALYSIS  Ivermectin/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
       Male  Middle Age  Strongyloides stercoralis/*DRUG EFFECTS
       Strongyloidiasis/*DRUG THERAPY/IMMUNOLOGY  Support, Non-U.S. Gov't
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

